Affinity Capital Management

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Sonitus Medical Inc. is a privately held medical device company based in San Mateo, California, focused on delivering innovative hearing solutions for patients with hearing difficulties. The company is recognized as an emerging leader in bone conduction hearing devices, particularly through its flagship product, the SoundBite Hearing System. This system is notable for being the world's first non-invasive and removable hearing solution, which transmits sound through the teeth, leveraging the principle of bone conduction. The device is FDA cleared as a prosthetic option for treating single-sided deafness and conductive hearing loss. Sonitus Medical aims to expand its technology for future applications, including mixed hearing loss and tinnitus, along with potential consumer and covert communication uses. Founded in June 2006, the company collaborates with otologists, ENTs, and audiologists to enhance the auditory experience for patients.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Baxano, Inc. develops minimally invasive tools to restore spine function and preserve healthy tissue. The company offers iO-Flex System, which targets and decompresses bone and soft tissue in the foramen, lateral recess, and central canal for patients with single and multi-level mild, moderate, and severe stenosis. Its products comprise Neuro Check device that allows the surgeon to confirm that the device is against the bone and the nerve is safely out of the way; MicroBlade ShaverTM instrument, which is used to remove the impinging bone and ligament; Guidewire; probes; and distal handles. The company was founded in 2005 and is based in San Jose, California.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.

ValenTx is a development-stage medical device company that focuses on minimally-invasive methods for the treatment of morbid obesity. The company was founded in 2002 and headquartered in Maple Grove, Minnesota.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

Primaeva Medical is a privately held venture capital funded company developing devices for dermatologists, plastic surgeons and other cosmetic/aesthetic physicians. Primaeva Medical is dedicated to providing the aesthetic physician superior new tools for Restoring Youth for their patients who want to reverse the signs of aging. In 2009 Primaeva will introduce a groundbreaking fractional radiofrequency system designed for the predictable treatment of aging skin.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Uptake Medical develops innovative medical technologies for the treatment of lung diseases. Its first product, InterVapor™, is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body’s natural healing process without leaving any foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

myocor is a medical company that develops and distributes a range of therapeutic products to its clients. The company develops and provides evaluations on technologies to treat mitral regurgitation and heart failure. Furthermore, the technologies assist in the improvement of cardiac function. myocor was founded in 1996 and is based in Minnesota.

Transneuronix, Inc. is a privately held medical device company focused on the treatment of obesity by stimulation of the stomach with an implantable pacemaker-like device.

Disc Dynamics is a healthcare company. They design and develop medical products. The Company offers surgical alternatives for the treatment of lower back problems and disc diseases. It offers DASCOR Disc arthroplasty system, a catheter-based minimally invasive nucleus replacement technology for the treatment of degenerated lumbar discs. Disc Dynamics was founded by Jeffrey Felt in 2000 and is headquartered in Eden Prairie, Minnesota.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Alliance Medical is a reprocessor of medical devices. The company was founded by Rick Ferreira and is based in Phoenix, Arizona.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Ican Inc., is a provider of Internet-based information and tools for health professionals.

Ican provides Internet-based information and tools for health professionals.

Agiliti provides world-class IT infrastructure and applications over the Internet. They offer flexible solutions built around your needs, with the expertise and vision to help grow your business in the direction you want Their IT services to take it. Managed applications, 24 x 7 server uptime, and end-to-end accountability for your systems – we’ll focus on your IT so that you can focus on your business. Flexibility, accountability, and vision, … the Agiliti answer to your IT challenges.